Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: WTAP

Gene summary for WTAP

Gene summary.

Gene information	Species	Human
	Gene symbol	WTAP
	Gene ID	9589
	Gene name	WT1 associated protein
	Gene Alias	Mum2
	Cytomap	6q25.3
	Gene Type	protein-coding
	GO ID	GO:0000375
	UniProtAcc	Q15007

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9589	WTAP	GSM4909285	Human	Breast	IDC	4.20e-09	-4.47e-01	0.21
9589	WTAP	GSM4909286	Human	Breast	IDC	2.78e-08	-2.13e-01	0.1081
9589	WTAP	GSM4909288	Human	Breast	IDC	1.46e-03	-4.52e-01	0.0988
9589	WTAP	GSM4909291	Human	Breast	IDC	1.46e-14	-6.05e-01	0.1753
9589	WTAP	GSM4909292	Human	Breast	IDC	2.24e-05	-7.57e-01	0.1236
9589	WTAP	GSM4909293	Human	Breast	IDC	7.75e-04	-2.96e-01	0.1581
9589	WTAP	GSM4909294	Human	Breast	IDC	3.32e-12	-5.67e-01	0.2022
9589	WTAP	GSM4909296	Human	Breast	IDC	3.72e-36	-7.32e-01	0.1524
9589	WTAP	GSM4909297	Human	Breast	IDC	9.34e-19	-3.45e-01	0.1517
9589	WTAP	GSM4909298	Human	Breast	IDC	4.93e-07	-3.86e-01	0.1551
9589	WTAP	GSM4909299	Human	Breast	IDC	3.74e-04	-3.22e-01	0.035
9589	WTAP	GSM4909301	Human	Breast	IDC	5.13e-08	-4.64e-01	0.1577
9589	WTAP	GSM4909302	Human	Breast	IDC	5.26e-25	-5.93e-01	0.1545
9589	WTAP	GSM4909304	Human	Breast	IDC	2.32e-06	-4.15e-01	0.1636
9589	WTAP	GSM4909305	Human	Breast	IDC	4.28e-02	-2.33e-01	0.0436
9589	WTAP	GSM4909306	Human	Breast	IDC	4.09e-10	-4.35e-01	0.1564
9589	WTAP	GSM4909307	Human	Breast	IDC	2.37e-17	-5.72e-01	0.1569
9589	WTAP	GSM4909308	Human	Breast	IDC	8.16e-11	-4.18e-01	0.158
9589	WTAP	GSM4909309	Human	Breast	IDC	1.21e-13	-4.67e-01	0.0483
9589	WTAP	GSM4909311	Human	Breast	IDC	1.47e-40	-7.04e-01	0.1534

Page: 1 2 3 4 5 6 7 8 9 10 11

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000037517	Prostate	BPH	RNA splicing, via transesterification reactions	114/3107	324/18723	2.19e-16	4.53e-14	114
GO:000037717	Prostate	BPH	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	112/3107	320/18723	6.21e-16	1.07e-13	112
GO:000039817	Prostate	BPH	mRNA splicing, via spliceosome	112/3107	320/18723	6.21e-16	1.07e-13	112
GO:004802418	Prostate	BPH	regulation of mRNA splicing, via spliceosome	51/3107	101/18723	3.74e-15	5.26e-13	51
GO:000038010	Prostate	BPH	alternative mRNA splicing, via spliceosome	35/3107	77/18723	2.89e-09	1.13e-07	35
GO:000038110	Prostate	BPH	regulation of alternative mRNA splicing, via spliceosome	29/3107	60/18723	1.16e-08	3.81e-07	29
GO:000838019	Prostate	Tumor	RNA splicing	153/3246	434/18723	9.15e-20	5.79e-17	153
GO:190331117	Prostate	Tumor	regulation of mRNA metabolic process	111/3246	288/18723	6.66e-18	2.30e-15	111
GO:004348419	Prostate	Tumor	regulation of RNA splicing	70/3246	148/18723	3.22e-17	1.05e-14	70
GO:000037518	Prostate	Tumor	RNA splicing, via transesterification reactions	119/3246	324/18723	3.40e-17	1.06e-14	119
GO:000037718	Prostate	Tumor	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	117/3246	320/18723	9.31e-17	2.22e-14	117
GO:000039818	Prostate	Tumor	mRNA splicing, via spliceosome	117/3246	320/18723	9.31e-17	2.22e-14	117
GO:005068416	Prostate	Tumor	regulation of mRNA processing	64/3246	137/18723	1.55e-15	2.75e-13	64
GO:004802419	Prostate	Tumor	regulation of mRNA splicing, via spliceosome	51/3246	101/18723	2.29e-14	2.97e-12	51
GO:000038015	Prostate	Tumor	alternative mRNA splicing, via spliceosome	35/3246	77/18723	9.41e-09	3.55e-07	35
GO:000038115	Prostate	Tumor	regulation of alternative mRNA splicing, via spliceosome	29/3246	60/18723	3.18e-08	1.02e-06	29
GO:000838027	Skin	AK	RNA splicing	111/1910	434/18723	1.85e-20	5.49e-17	111
GO:190331125	Skin	AK	regulation of mRNA metabolic process	81/1910	288/18723	7.27e-18	8.61e-15	81
GO:004348428	Skin	AK	regulation of RNA splicing	54/1910	148/18723	9.66e-18	9.53e-15	54
GO:000037526	Skin	AK	RNA splicing, via transesterification reactions	85/1910	324/18723	1.16e-16	7.62e-14	85

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

WTAP

SNV

Missense_Mutation

c.152N>C

p.Asp51Ala

p.D51A

Q15007

protein_coding

tolerated(0.07)

possibly_damaging(0.78)

TCGA-A2-A04P-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

taxol

WTAP

SNV

Missense_Mutation

c.236G>A

p.Arg79Gln

p.R79Q

Q15007

protein_coding

deleterious(0.04)

benign(0.38)

TCGA-A8-A07R-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Ancillary

zoledronic

WTAP

SNV

Missense_Mutation

rs375840138

c.1001N>T

p.Ala334Val

p.A334V

Q15007

protein_coding

tolerated_low_confidence(0.33)

benign(0)

TCGA-D8-A1J8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

nolvadex

WTAP

SNV

Missense_Mutation

c.485N>C

p.Arg162Pro

p.R162P

Q15007

protein_coding

deleterious(0)

possibly_damaging(0.899)

TCGA-D8-A1XB-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

WTAP

SNV

Missense_Mutation

rs369657864

c.932A>G

p.Asn311Ser

p.N311S

Q15007

protein_coding

tolerated_low_confidence(0.51)

benign(0.025)

TCGA-XX-A89A-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WTAP

insertion

Nonsense_Mutation

novel

c.573_574insCCAACTGCACTCCAGCCTGGGCTACAGAGTGAGACTCCATCCTAA

p.Lys191_Lys192insProThrAlaLeuGlnProGlyLeuGlnSerGluThrProSerTer

p.K191_K192insPTALQPGLQSETPS*

Q15007

protein_coding

TCGA-A2-A04P-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

taxol

WTAP

insertion

Frame_Shift_Ins

novel

c.929_930insCTTGCTTTGTGGCAGGCAC

p.Asn311LeufsTer7

p.N311Lfs*7

Q15007

protein_coding

TCGA-A8-A06X-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WTAP

insertion

Frame_Shift_Ins

novel

c.931_932insAAGAAACATTTTTCAATGTT

p.Asn311LysfsTer26

p.N311Kfs*26

Q15007

protein_coding

TCGA-A8-A06X-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WTAP

SNV

Missense_Mutation

novel

c.1082A>G

p.Asp361Gly

p.D361G

Q15007

protein_coding

deleterious_low_confidence(0.01)

benign(0.084)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

WTAP

SNV

Missense_Mutation

c.448N>C

p.Asp150His

p.D150H

Q15007

protein_coding

deleterious(0.03)

probably_damaging(0.98)

TCGA-DG-A2KK-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1